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Arginase is a metalloenzyme which hydrolyzes L-arginine to L-ornithine and urea. Since its discovery, in the early 1900s, this
enzyme has gained increasing attention, as literature reports have progressively pointed to its critical participation in regulating
nitric oxide bioavailability. Indeed, accumulating evidence in the following years would picture arginase as a key player in vascular
health. Recent studies have highlighted the arginase regulatory role in the progression of atherosclerosis, the latter an essentially pro-
oxidant state. Apart from the fact that arginase has been proven to impair different metabolic pathways, and also as a consequence
of this, the repercussions of the actions of such enzyme go further than first thought. In fact, such metalloenzyme exhibits direct
implications in multiple cardiometabolic diseases, among which are hypertension, type 2 diabetes, and hypercholesterolemia.
Considering the epidemiological repercussions of these clinical conditions, arginase is currently seen under the spotlights of the
search for developing specific inhibitors, in order tomitigate its deleterious effects.That said, the present review focuses on the role of
arginase in endothelial function and its participation in the establishment of atherosclerotic lesions, discussing the main regulatory
mechanisms of the enzyme, also highlighting the potential development of pharmacological strategies in related cardiovascular
diseases.
1. Introduction
Cardiovascular and metabolic diseases have achieved global
emphasis and represent one of the main public health
problems [1–3]. The augmented burden of such conditions is
due to the increase of their risk factors in alarming epidemic
proportions, becoming an important cause of morbidity and
mortality in occidental countries. In this scenario, atheroscle-
rosis is recognized as a hallmark in the development of key
cardiovascular disorders, including myocardial infarction
and stroke [3–5].
Thereby, many studies have aimed to elucidate the patho-
physiological mechanisms involved in the onset and devel-
opment of these diseases, highlighting the role of endothelial
dysfunction in vascular disorders, which is mainly caused by
the reduced bioavailability of nitric oxide (∙NO; ∙N=O nitro-
genmonoxide) [6].When it comes to the ∙NO bioavailability,
it is of note to emphasize the role of the semiessential amino
acid L-arginine, a common substrate for both nitric oxide
synthase (NOS) and arginase enzymes [7].
In a pioneer work, Buga and coworkers showed that the
NG-hydroxy-L-arginine, an intermediate compound in the
process of ∙NO synthesis from L-arginine, is an endogenous
inhibitor of arginase activity [8]. In this context, it becomes
evident the important role of these metabolic enzymes,
with the necessity to keep the balance for the axis NOS/L-
arginine/arginase for maintaining the ∙NO homeostatic lev-
els. The two fundamental mechanisms for reduced levels
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Figure 1: Workflow: steps for articles selection and for preparing the paper.
of bioactive ∙NO are its reduced synthesis by NOS and its
increased oxidative inactivation by reactive oxygen species
(ROS) intermediates, ultimately leading to a potential impair-
ment in cardiovascular homeostasis [9].
Mammalian arginase (EC 3.5.3.1), a manganese-metallo-
enzyme [10], hydrolyzes L-arginine to L-ornithine and urea
[11].
By presenting this action on L-arginine, arginase partic-
ipates in the regulation of the ∙NO synthesis by using the
same enzyme substrate for the three known NOS isoforms:
neuronal NOS (nNOS or NOS-1), inducible NOS (iNOS
or NOS-2), and endothelial NOS (eNOS or NOS-3) [12].
Thus, increased expression of arginase may imply extensive
consumption of L-arginine to be converted into urea and L-
ornithine, this way reducing the availability of L-arginine to
∙NO synthesis by NOS.
Various studies have demonstrated increase in arginase
activity in different clinical conditions, such as hypertension
[13, 14], type 2 diabetesmellitus [15, 16], hypercholesterolemia
[17], aging [18–20], and atherosclerosis [21], proposing a
critical contribution of this enzyme in the pathogenesis of
cardiovascular diseases. In this direction, the present review
focuses on the role of arginase in atherosclerosis and its
implications in endothelial function, aiming to contribute
to the pathophysiological discussion of the main regulatory
mechanisms of the enzyme. Also, the paper highlights the
potential development of pharmacological actions in related
cardiovascular diseases concerning the arginase activity. For
carrying out this study, a research in electronic PubMed
database was performed taking as reference the period
between the year 1900 and January 25, 2014, using the
terms “arginase AND endothelial dysfunction,” and “arginase
AND endothelial dysfunction AND atherosclerosis.” Only
articles available in English were considered (Figure 1). In
the following lines, the term “arginase” will be used to refer
to both isoforms of the enzyme, so that arginase I will be
specifically presented by the term “Arg I,” and the second one,
by “Arg II.”
2. From the Discovery of Arginase to
Its Role in Endothelial Dysfunction:
More Than a Century of History
The seminal events of the history of arginase took place more
than a hundred years ago. In 1904, Kossel and Dakin [22]
described the discovery of this enzyme in mammalian liver.
They observed a decrease of arginine after acid hydrolysis
in the liver caused by administration of the ferment named
arginase, generating urea and ornithine [11, 22].Thenceforth,
other researches have reported the presence of arginase in
various organs. In the first decades of 1900, arginase was
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found in the liver of several animal classes such as amphib-
ians, fishes, and turtles by Clementi, who also identified the
presence of the enzyme in the kidney of birds.
A few years after Clementi’s observations [23–25], the
records concerning the spectrum of arginase distribution
in different organs of certain mammals and domestic fowls
were broadened by Edlbacher and Rothler [26], as both
authors conducted a large study which brought to light the
identification, in mammals and birds, of arginase in the
liver, kidneys and testes. Besides showing that the number
of units of arginase normalized by body weight differed
between sexes, being elevated in males when compared to
females, the authors also reported the presence of arginase
in the placenta and thymus of some mammals. Later on, in
1927, Chaudhuri performed a study in 32 birds showing a
quantitative estimation of arginase mainly in kidneys and
then in testes. He also defended a gender distinction in the
arginase distribution due to the presence of this enzyme in
male sexual organs and the absence in female ones [27]. In
the following years, the differential role of arginase between
sexes and the participation of sex steroid hormones in its
modulation would also be discussed, pointing to the possible
effects of arginase in multiple pathophysiological pathways
[28].
In 1930, it was reported the activation of arginase bymetal
complexes of thiols, such as reduced glutathione and Fe+2
and Cu+2 ions. However, Purr and Weil [29] suggested that
a specific oxidation-reduction potential, and not only the
SH group, was related to arginase activation [29]. In 1986,
Dizikes and coworkers published the screening of human
liver arginase cDNA, which was not completely homologous
to the genes found in the human kidney [30]. Such apparent
discrepancy was posteriorly ruled out when the sequence
found in the kidney was described as the gene of Arg II,
cloned in 1996 [31]. Throughout the years, several studies
have demonstrated the presence of arginase not only in
various organs and species but also in animal models related
to vascular disorders [20, 21, 32–38]. Buga and coworkers,
for example, demonstrated for the first time the constitutive
expression of arginase in rat aortic endothelial cells, also
observing that its endogenous inhibition may represent a
means for enabling the availability of proper amounts of
arginine for ∙NOproduction [8]. Furthermore, by comparing
young and old Wistar rats, Berkowitz and coworkers first
showed the association between arginase activity and the
endothelial dysfunction of aging [20]. Following these break-
throughs in the comprehension of arginase contribution
to vascular health, Ryoo and coworkers [21] discussed the
connections among atherosclerosis, arginase activity, and
endothelial dysfunction in atherosclerosis-prone mice, high-
lighting the therapeutic potential of arginase in atheroscle-
rotic vascular disease [21]. Nevertheless, the pathophysio-
logical mechanisms concerning the arginase participation in
different metabolic diseases are not completely understood
and the researches in humans still require further advances in
order to better define the molecular pathways through which
arginase interferes in health and disease.
3. In the Backstage of the Enzyme Function:
Expression, Regulation of Arginase, and
the Crosstalk in the Signaling Pathways
Arginase is an enzyme that participates in the urea cycle,
being described in two isoforms: Arg I and Arg II, both of
them catalyzing the same biochemical reaction. Human Arg
I is a 322-amino acid protein, sharing 58% sequence with
her sister, Arg II [39]. Arg I is known as the hepatic isoform
because it is primarily found in the liver [40, 41]. However,
it has been described in other tissues such as endothelial
cells and vascular smooth muscle cells (VSMC), being also
a cytosolic enzyme [42]. On the other hand, in mammalians,
Arg II is a mitochondrial enzyme and is distributed in several
organs and tissues, including prostate, kidney [39], and blood
vessels. Their isoforms are expressed in the vasculature,
as well as have many actions that interfere with vascular
dynamics and contribute to endothelial dysfunction found in
various cardiovascular pathologies [21].
In the course of the enzyme activity, the hydrogen bond-
ing established between the guanidinium group and Glu227
keeps L-arginine in its proper position/location in the active
site of the enzyme. Such molecular interaction is critical for
enabling L-arginine to be attacked by the metal-associated
hydroxide ion at the guanidinium group, leading to the
formation of a tetrahedral intermediate. Thus, the hydroxyl
group in that intermediate and the developing sp3 lone elec-
tron pair on the NH
2
group are stabilized by the manganese
ions [10].
According to the aforementioned statements, in the
endothelial layer, the competition between Arg II and eNOS
leads to a decrease in the ∙NO bioavailability, resulting in
impaired vasodilation and, consequently, endothelial dys-
function [20, 21]. The consumption of L-arginine also stim-
ulates the production of reactive oxygen species (ROS),
greatly contributing to oxidative stress. In addition, arginase
induces the synthesis of polyamines and proline, promoting
VSMC proliferation and remodeling [43, 44]. It has also been
reported that the overexpression of Arg I reduced inflam-
matory activity in rabbits, via interaction with endothelial
nitric oxide synthase (eNOS) [45]. Furthermore, it has been
reported that conditions such as hypoxia [46], as well as
proinflammatory mediators [47], reactive oxygen and nitro-
gen species (RONS), glucose, and oxidized low-density
lipoprotein (ox-LDL) [40] stimulate arginase expression.
Together, factors including stimulation and expression of
this enzyme provide a framework for the analysis of the
arginase isoforms into the atherogenesis. In endothelial cells,
the abovementioned inducing phenomena are particularly of
note, once the reduction in L-arginine levels is presented as
one of themainmechanisms whichmay lead to the establish-
ment of endothelial dysfunction [45]. Accordingly, several
signaling pathways involve the activation of arginase, such
as receptors for ox-LDL [21, 48], inflammatory mediators,
and RhoA/ROCK kinases [45]. At first, after the oxidation
of LDL, the resulting lipoprotein binds to the lectin-like LDL
receptor-1, LOX-1, stimulating the activation of arginase [21].
Furthermore, ox-LDL increases the expression of caveolin I,
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amolecule that interacts with eNOS, hindering the formation
of ∙NO [48, 49].
With regard to inflammatory mechanisms, macrophages,
cells involved in the generation of the atheromatous plaque,
induce the expression of arginase via lipopolysaccharide
(LPS), interleukin (IL)-4, IL-6, and interferon-gamma (INF-
𝛾) [45]. In addition, in inflammatory conditions, cationic
amino acid transporters (CAT), which act as L-arginine
transporters, have their function impaired, then reducing the
production of ∙NOand consequently promoting the progres-
sion of atherosclerosis [50]. Moreover, the route RoA/ROCK
corresponds to a cascade of intracellular signaling through
which protein kinases, stimulated by various factors, such
as proinflammatory cells, ROS, and ox-LDL, induce the
activation of arginase [45, 51].
4. Vascular Dysfunction in Atherosclerosis:
A Brief Update
The endothelium is a central component for the maintenance
of cardiovascular homeostasis. For a long time, it was thought
that the vascular endothelium predominantly would act as
a surface for blood flow. In a landmark study, Furchgott
and Zawadzki [52] changed this concept. These authors
first demonstrated the existence of an endothelium-derived
relaxing factorwhichwas subsequently identified as ∙NO[53–
55]. Further work showed that the endothelium is an active
participant in the regulation of cardiovascular homeostasis
[56]. The network involved in the endothelial regulation is
complex. Under physiological conditions, this cell layer is a
sensor of hemodynamic changes and releases both relaxing
and contracting factors. The disturbance in this sensitive
balance leads to endothelial dysfunction, a common feature
in cardiovascular, renal, and metabolic diseases [57], as well
as in the atherosclerotic plaque formation [4, 58].
Atherosclerosis represents a multifactorial process and
one of the well discussed marks of this structural and
functional phenomenon is the role of cholesterol and inflam-
matory mediators in atheroma formation [3, 5]. Currently, it
is defined as a chronic and progressive disease in which the
deposition of atherosclerotic plaques occurs on the inner face
of great arteries, causing reduction of the vascular lumen and
damage to the underlying layers [3, 4].
The initial step in the formation of an atherosclerotic
plaque is characterized by damage, either structural or func-
tional, in the inner surface of the arteries, which promotes
the increased expression of adhesionmolecules in the surface
of endothelial cells, thereby stimulating leukocyte adhesion
to the intima layer. In the establishment of this process,
proinflammatory mediators and shear stress play an impor-
tant role, favoring this adherence. After physically contacting
the endothelial cells, the adhered monocytes may infiltrate
the subendothelial space via migration. Concomitantly, an
accumulation of LDL particles in that space may also occur.
In the presence of oxidative stress, the increased amounts
of ROS, among which superoxide anion (∙O
2
−), lead to the
oxidation of such lipoproteins (ox-LDL). The circulating
monocytes, now recruited and turned into macrophages in
the subendothelial space, progressively phagocyte ox-LDL
particles, ultimately being converted in foam cells. In this
process, VSMC are stimulated to migrate from the tunica
media to the intima, producing a cape of collagen and elastin
that covers the plaque. Additionally, it is also observed the
formation of a necrotic core due to debris and lipids released
from cells that suffered apoptosis [5, 59].
Experimental and clinical evidence show that the major
risk factors implicated in the impairment of cardiovascular
functions are directly associatedwith endothelial dysfunction
[56, 60, 61].The seminal experiments of Ludmer and cowork-
ers [58], using angiography, characterized the paradoxical
effect of acetylcholine (ACh) in the coronary circulation, as
this study showed that, in patients with atherosclerosis, this
muscarinic agonist significantly decreased vascular diameter.
The authors postulated that the impairment in endothelial
function is responsible for vasoconstriction observed after
intracoronary administration of ACh [58].
The link between endothelial cells and the elementary
changes in the vascular wall which precede the establishment
of the atherosclerotic process has passed from drafted specu-
lations to concrete evidences, once some studies have clearly
shown the connection between endothelial dysfunction and
the early development of atherosclerosis [5, 45]. In order
to elucidate the relationship between ∙NO and endothelial
dysfunction in atherosclerosis, for example, Dhawan and
colleagues [62] demonstrated a decrease in atherosclerotic
plaque formation in an experimental model with mon-
keys fed a high-cholesterol diet after administration of L-
arginine, with improved endothelial function by elevation
of ∙NO levels and thereby reduced atherogenesis. In this
context, several studies have been conducted to characterize
the relationship between arginase and the cardiovascular
endpoint of progressive endothelial dysfunction, marked by
atherosclerosis.
Taking into account that the regulation in ∙NO metab-
olism represents a mediator for vascular health [63] and
that arginase activity in particular conditions may play “the
bad guy” by compromising the ∙NO bioavailability [7, 9], it
becomes easy to understand the reasonwhy the ∙NO/arginase
axis is now recognized as a pivotal regulatory pathway of the
vascular system. Indeed, for arginase activity there is only
one substrate, L-arginine, but the repercussions of this single
action may reach massive proportions, implying pleiotropic
harmful outcomes on the endothelial function, once the
beneficial effects of ∙NO, among which the prevention of
abnormal vasoconstriction, inhibition of platelets aggrega-
tion, and reduced expression of adhesion molecules in the
surface of endothelial cells [64], could be nullified.
5. Role of Arginase in the Development of
Endothelial Dysfunction and Atherosclerosis
Studies have demonstrated an increase in the regulation of
arginase in various cardiometabolic diseases such as hyper-
tension [65–67], atherosclerosis [15, 21], ischemia-reperfu-
sion injury [36, 68], diabetes mellitus [15, 57], and ageing [20,
69]. These findings have prompted researchers to discover
whether arginase inhibition would then result in improved
endothelial function in these conditions.
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As previously discussed, a decrease of the ∙NO bioavail-
ability plays an essential role in the pathogenesis of various
cardiovascular events [70]. Interestingly, endothelial dys-
function derived from the ∙NO reduction causes vascular
stiffness even in the absence of atherosclerosis, with arginase
presenting itself as a key element in the progression of
vascular disorders [71] (Figure 2).
Arginase acts in atherogenesis mostly via reduction of
∙NO, a free radical responsible for the inhibition of platelet
aggregation and leukocyte adhesion to the blood vessel wall,
being an important factor in the formation of atherosclerotic
plaque [5]. Furthermore, ∙NO helps in the preservation
of endothelial function due its vasodilator effect, so that
its deficiency corresponds to another mark that leads to
the progression of atherosclerosis [72] (Figure 2). Ryoo and
coworkers [21], while studying the role of Arg II in atheroscle-
rosis, found that ox-LDL, frequently observed in this disease,
stimulates the release of Arg II, reducing the production of
∙NO. In such work, the researchers used mice with genetic
deletion for Arg II (Arg II−/−) fed a high-cholesterol diet,
observing that the reduction in arginase activity improved
the endothelial function compared to ApoE−/− mice fed the
same diet. These findings suggest that the genetic deletion
of arginase provides endothelial protection. Another crucial
atherosclerotic pathophysiologicalmechanism consists in the
oxidation of LDL particles [40, 48], that contributes to the
formation of foam cells, after being captured by phagocytes.
This also participates in the formation of ROS via NADPH
oxidase [73] and uncoupling of eNOS [40], hindering the
∙NO production. In addition, it was shown that hypercholes-
terolemia increases the generation of asymmetrical dimethyl-
L-arginine (ADMA), an endogenous inhibitor of eNOS
[9, 64], in experimental models with monkey, inhibiting
competitively the binding of L-arginine to eNOS [74].
ox-LDL causes a separation of arginase from the micro-
tubule cytoskeleton, then increasing the expression of this
enzyme in human aortic endothelial cells (HAECs) [40].
Ryoo and colleagues [48] showed that the isoform in question
corresponds to Arg II via LOX-1 receptor. Furthermore, as
a consequence of arginase activity in the formation of the
atherosclerotic plaque, it is observed a reduction in ∙NO
levels, thereby inducing the oxidation of LDL (which gen-
erates a stimulatory form of atherogenesis) and other effects
such as increased endothelial permeability, cell proliferation,
and leukocyte adhesion on the vasculature, resulting in
atherosclerosis [75].
Several studies have reported endothelial dysfunction
as a consequence of increased activity and/or expression
of arginase in experimental models of hypertension [70],
diabetes mellitus [15], aging [20], erectile dysfunction, sickle
cell disease, and atherosclerosis [70], the latter corresponding
to the focus of this paper. In Arg II null mice, for example,
this enzyme activity was substantially reduced in the vascular
endothelium, suggesting that Arg II is the main isoform
present in blood vessels. Also, the inhibition ofArg II restored
endothelial function, led to increased vascular ∙NO levels and
decreased vascular stiffness in ApoE−/− mice [21]. Moreover,
even in ApoE−/− mice, the high-cholesterol diet increased
arginase activity compared with control mice fed a standard
diet. In addition, inhibition of Arg II prevented the ∙NO
decrease induced by high-cholesterol diet [21].
The rise of RONS due to the increased expression of
arginase has emerged as one of the factors that induce
endothelial dysfunction in animal models of atherosclerosis
[41], a fact that has also been observed in patients with coro-
nary artery disease and vascular impairment in type 2 dia-
betes mellitus [76]. However, it is not completely understood
how arginase acts on endothelial dysfunction in vivo [15].
An established concept, however, defines that the produc-
tion of RONS is also stimulated by inflammatory conditions,
leading to endothelial injury and consequent development of
atherosclerosis [50].
The formation of ROS is reported as a hallmark in the
physiopathology of atherosclerosis. In this regard, the oxida-
tive modification hypothesis as a critical step in the develop-
ment of atherosclerosis deserves to be mentioned. According
to this hypothesis, the simple presence of circulating LDL
particles is not the only initial influencing factor for the
onset of atheromatous plaques. Instead, such particles are
required to undergo structural changes so that they can be
properly recognized by specific macrophage receptors, being
then engulfed and accumulated in phagocytes [77, 78]. In line
with these observations, several studies have demonstrated
the role of ox-LDL and proinflammatory mediators in the
generation of atheromatous plaque [5]. One of the mecha-
nisms arising from these stimuli corresponds to apoptosis
of endothelial cells, which contributes to the induction of
atherogenesis. Given this context, Suschek and coworkers
[50] demonstrated that the expression of IL-1, tumor necrosis
factor alfa (TNF-𝛼), and INF-𝛾 in blocked iNOS rat models
resulted in cell apoptosis induced by hydrogen peroxide
(H
2
O
2
), whereas under conditions of high levels of ∙NO, no
protection against cell death was observed, concluding that a
greater supply of L-arginine helps to reduce the development
of atherosclerosis [50].
As previously outlined, endothelial dysfunction and
atherosclerosis are directly linked to proinflammatory states
in blood vessels. Several cytokines, such as IL-4, IL-6, and
TNF stimulate the activity of arginase and impair the expres-
sion of eNOS [79], besides increasing the production of ROS
(Figure 2). Concerning this issue, Spillman and colleagues
[80] investigated the relationship between liver X receptors
(LXR), a hormone receptor that participates in the reverse
transport of cholesterol and TNF upregulation, demonstrat-
ing a decrease inArg II activity andmRNAexpression by LXR
agonist, with restoration of ∙NO bioavailability.
In another study focused on inflammatory factors
involved in endothelial dysfunction, Witting and coworkers
[81] showed an increase in arginase protein expression and
activity in rat aorta exposed to protein serum amyloid A
(SAA), an apolipoprotein produced by the liver that is
deposited in atherosclerotic plaques and is costimulated by
inflammatorymediators such as TNF-𝛼, IL-1, and IL-6. Rein-
forcing the critical role of arginase in the metabolism of ∙NO,
experiments conducted by Sikka and coworkers [12] showed
that, in C57Bl/6 mice exposed to cigarette smoke for 2 weeks,
the knockout mice for Arg II showed better endothelial
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function compared to the controls. This observation was
attributed to the gene deletion of Arg II and the consequent
increase in ∙NO bioavailability [12] (Figure 2).
One of the mechanisms that lead to endothelial dysfunc-
tion is characterized by shear stress, reported as a predis-
posing factor for plaque formation. In a novel study with
porcine endothelial cells and carotid artery, Thacher and
colleagues [82] demonstrated an increase of Arg II expression
after the induction of oscillatory shear stress compared to
unidirectional high shear stress, for three days. To corrob-
orate the role of this enzyme with the related alteration
in the blood flow, the arginase inhibitor Nw-hydroxy-nor-
L-arginine (Nor-NOHA) was administered, resulting in a
decrease in ROS production [82]. Furthermore, an elevated
proliferation of VSMCwas also observed. With regard to this
effect, Xiong and coworkers [83] studied the role of Arg II
in VSMC from human umbilical veins, also demonstrating
a proliferative action in these cells when the enzyme was
activated. However, the authors observed an induction to
senescence and apoptosis in the lack of Arg II function,
contributing to the rupture of the plaque burden, due to the
resulting weakness of the vascular layers [83] (Figure 2).
With regard to arginase stimulation, the administration
of thrombin in human umbilical vein cells was able to elevate
this enzyme expression after 18 hours of exposure, with
peak in 24 hours [84]. In this study, it was also admin-
istered the HMG-CoA inhibitor fluvastatin, which impairs
the RhoA/ROCK pathway, leading to reduction of arginase
expression by thrombin. In addition, similar effects were
observed with other ROCK inhibitors used in the study [84].
Also, while studying the role of Arg II in the macrophage
inflammatory responses, Ming and coworkers found a pro-
tective profile against insulin resistance, type 2 diabetes, and
atherosclerosis in Arg II-deficient mice [38]. In addition,
by comparing the vascular function between transgenic
C57Bl/6 mice overexpressing human Arg II and nontrans-
genic controls, Vaisman and colleagues [70] found impaired
endothelium-dependent vasodilation induced by ACh in
the transgenic group. The authors also observed that the
increased expression of Arg II itself, irrespective of changes
in lipid concentrations in plasma, was sufficient to feed the
development of atherosclerotic lesions, ultimately highlight-
ing the critical role of Arg II in such inflammatory process.
Aside from being described as a potentially deleterious
enzyme in the regulation of endothelial function, of great
importance are also the observations that arginase may exert
beneficial effects in the vasculature. Such capacity of, in
specific circumstances, embodying both a protective and
harmful role, inserts arginase in an even more complex and
intriguing context. In rabbits, for example, while studying
genes of atherosclerosis susceptibility, Teupser and coworkers
[85] showed that the high expression of Arg I inmacrophages
contributes to atherosclerosis resistance, possibly by exerting
an anti-inflammatory mechanism in the vascular environ-
ment [85]. Furthermore, the atheroprotective role of Arg
I may be expressed through multiple pathways, such as
differential activation ofmacrophages, modulation of inflam-
matory response in VSMC, and changes in plaque stability
[41].
All original studies assessed in the present paper, con-
cerning the role of arginase isoforms in the binomial endothe-
lial dysfunction-atherosclerosis, are presented in Table 1.
6. The Therapeutic Potential of Arginase:
A Short Update
Arginase inhibitors have been developed since the 1990s, to
evaluate more accurately the effects of the enzyme activity
reduction [86], with the observation of promising results
concerning the improvement in endothelial function and
associated disorders in animal models of diabetes [34],
hypercholesterolemia [87], hypertension [32, 37, 88], and
metabolic syndrome [88].
Therefore, the elucidation of mechanisms involved in
the transcription and transduction, as well as in activity of
arginase represents a promising area for the development of
pharmacological approaches in cardiovascular andmetabolic
diseases [45, 86]. Despite the growing number of studies
and the evident role of arginase in the regulation of ∙NO
bioavailability [8, 68, 89, 90] and endothelial dysfunction
[20, 33, 91], development of atherosclerosis [21, 40], and other
cardiometabolic diseases [34, 37, 57, 92], several questions
still need to be better understood.
In fact, a major obstacle for a more accurate under-
standing of the effects of the two different human arginases
still rests on the difficulty in creating a specific inhibitor for
each isoform, due to the close similarity of chemical struc-
ture between them, which contains almost identical metal
clusters and active site configuration [86]. In addition, the
nonspecificity of the inhibitors becomes a challenge in studies
with animals, as well as for future clinical trials, because the
unspecific inhibition would not enable to define for sure to
which isoform the observed effects could be attributed.
In this scenario, despite the encouraging findings con-
cerning enzyme inhibition, the use of arginase inhibitors
still claims for advances, since the pharmacological agents
currently available are not isoform-specific. This fact is of
particular importance, considering the differential organic
distribution, concentrations, and specific actions of arginase
isoforms, as stated above.
So far, different studies have already pointed to the
potential of arginase inhibition, either directly or indirectly.
In rats presenting with metabolic syndrome treated with
arginase inhibitors (citrulline, norvaline, and ornithine), for
example, it was observed amelioration in blood pressure
levels directly by increase in ∙NO bioavailability and indi-
rectly by inhibition of insulin resistance and hypertriglyc-
eridaemia [88]. Also, Holowatz and Kenney demonstrated
that essential hypertension in humans was associated with
attenuated reflex cutaneous vasodilation and that acute inhi-
bition of arginase improved such reflex [93]. Similarly, oral
administration of atorvastatin for three months was capable
of restoring cutaneous microvascular function in hyperc-
holesterolaemic patients, with the improvement observed
mediated by decreased arginase activity [94]. Taken together,
these observations highlight themultipleways throughwhich
arginasemay be targeted in order to improve cardiometabolic
profiles.
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7. Conclusions and Perspectives
In summary, increases in arginase expression and/or activity
undoubtedly repercute in the atherosclerosis physiopathol-
ogy, mainly by regulating the ∙NO production via eNOS, so
that the upregulation of arginase favors the formation of the
atherosclerotic plaque [95].
Thus, further studies are required to explain the degree
with which arginase contributes in the intrinsic mechanisms
of endothelial dysfunction, principally in the clinical setting.
In this regard, clinical research is still limited, with fewhuman
studies that assessed the role of arginase in atherosclerosis.
Indeed, by allowing the dissection of the molecular and
metabolic pathways trodden by the actions of such enzyme,
this investigation represents a promising field for developing
new targeted therapies for different clinical conditions.
Finally, considering the amount of knowledge that has
been accumulated in the last decades, pointing to the well-
recognized participation of arginase in the onset and develop-
ment of endothelial dysfunction and cardiovascular diseases,
a myriad of fresh perspectives under the molecular point
of view was opened widely right before our eyes. If in 1927,
Chaudhuri would say that “As regards the function of the
enzyme, very little is as yet known except that it hydrolyses
arginine into ornithine and urea” [27], the increasing atten-
tion given to that newborn and mysterious enzyme in the
following years would change that statement dramatically.
The pieces of this puzzle were randomly spread on Kossel
and Dakin’s table, inciting the curiosity of other pioneer
researchers in the study of arginase from the first half of the
twentieth century. It is our work, from now on, to keep on
putting themback together, once recent advances in the study
of the triad arginase/endothelial dysfunction/atherosclerosis
have shown that these pieces, little by little, have finally began
to fit properly with each other. It is not possible to foresee
what the future might hold, but it seems to be just a matter
of time for us to evidence so many other hidden connections
linking the paths of this journey and learn asmuch as possible
from what they can tell us.
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